Welcome to precisionFDA

Brain cancer is the tenth leading cause of death among both men and women, and the second most common cancer among children between the ages of 0-14. Successfully treating brain cancer can be very challenging due to drug delivery impediments caused by the blood-brain barrier. Additionally, location of the brain tumor may prohibit surgical interventions aimed to prevent further cancer-related complications. Recently, targeted therapies, drugs that block specific enzymes, protein, or other molecules (called biomarkers) involved in the growth and spread of cancer cells, have shown promise in the treatment of different cancer types. Researchers are currently investigating the effectiveness of targeted therapies for brain cancer, including Bevacizumab and Everolimus. It is critical that the scientific community continue to identify and validate biomarkers to allow for modern clinical trials to be designed based on the matching of tumor molecular features with targeted therapeutics. Here is your chance to make a difference by helping identify novel biomarkers for brain tumor prognosis. Georgetown's Lombardi Comprehensive Cancer Center, Innovation Center for Biomedical Informatics and the FDA have partnered to bring you the precisionFDA Brain Cancer Predictive Modeling and Biomarker Discovery Challenge. Details available [here!](https://precision.fda.gov/challenges/8) [read more at the full blog]